Resource Summary Report

Generated by RRID on Aug 27, 2026

M14

RRID:CVCL_1395
Type: Cell Line

Proper Citation

RRID:CVCL_1395

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1395

Proper Citation: RRID:CVCL_1395

Description: Cell line M14 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Amelanotic melanoma

Defining Citation: PMID:56444, PMID:204583, PMID:945229, PMID:954005, PMID:1260767, PMID:1918136, PMID:2041050, PMID:2060184, PMID:3046746, PMID:3658923, PMID:3674770, PMID:6470027, PMID:6500744, PMID:6876798, PMID:8618233, PMID:8631022, PMID:9331090, PMID:10700174, PMID:11121133, PMID:12068308, PMID:15748285, PMID:17088437, PMID:18277095, PMID:19372543, PMID:19549886, PMID:19727395, PMID:19799798, PMID:21863025, PMID:22068913, PMID:22347499, PMID:22384151, PMID:22628656, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24670534, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:28940260, PMID:29492214, PMID:30894373, PMID:30971826, PMID:31733513, PMID:38861359

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: M14

Synonyms: M14-MEL, UCLA-SO-M14, UCLA SO M14, UCLA-SO-14, UCLASO-M14, Melanoma 14, M-14

Cross References: BTO:BTO_0002805, EFO:EFO_0003056, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioSample:SAMN06129842, cancercelllines:CVCL_1395, Cell_Model_Passport:SIDM00003, ChEMBL-Cells:CHEMBL3307591, ChEMBL-Targets:CHEMBL614317, CLS:302163, Cosmic:686479, Cosmic:687445, Cosmic:875889, Cosmic:897467, Cosmic:905975, Cosmic:974068, Cosmic:974261, Cosmic:1022278, Cosmic:1044265, Cosmic:1092611, Cosmic:1109808, Cosmic:1132591, Cosmic:1158815, Cosmic:1295340, Cosmic:1303040, Cosmic:1305365, Cosmic:1312348, Cosmic:1459642, Cosmic:1537485, Cosmic:1888913, Cosmic:1998453, Cosmic:2791112, Cosmic-CLP:905975, DepMap:ACH-002159, EGA:EGAS00001000978, GDSC:905975, GEO:GSM2140, GEO:GSM50201, GEO:GSM50263, GEO:GSM188222, GEO:GSM188252, GEO:GSM188311, GEO:GSM743464, GEO:GSM750799, GEO:GSM799352, GEO:GSM799415, GEO:GSM844583, GEO:GSM847034, GEO:GSM1153422, GEO:GSM1178326, GEO:GSM1178327, GEO:GSM1181292, GEO:GSM1181336, GEO:GSM1670072, GEO:GSM2124668, IARC_TP53:18085, NCI-DTP:M14, PharmacoDB:M14_879_2019, PRIDE:PXD003539, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, Progenetix:CVCL_1395, PubChem_Cell_line:CVCL_1395, SKY/M-FISH/CGH:2813, Wikidata:Q51838638

ID: CVCL_1395

Record Creation Time: 20220427T220740+0000

Record Last Update: 20260815T234530+0000

Ratings and Alerts

No rating or validation information has been found for M14.

No alerts have been found for M14.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Shi HZ, et al. (2026) BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(28), e14590.

Nicolini F, et al. (2025) Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients. Frontiers in immunology, 16, 1636722.

Kim DY, et al. (2025) Identification of UBE3C as an E3 ubiquitin ligase for mutant BRAF. Life sciences, 378, 123827.

Kosharek AT, et al. (2025) In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma. PloS one, 20(8), e0330200.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Park JA, et al. (2023) Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. Journal for immunotherapy of cancer, 11(3).

Tao L, et al. (2023) Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma. Frontiers in cell and developmental biology, 11, 1171047.

Park JA, et al. (2022) Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. Journal for immunotherapy of cancer, 10(1).

Kline CD, et al. (2022) MITF Is Regulated by Redox Signals Controlled by the Selenoprotein Thioredoxin Reductase 1. Cancers, 14(20).

Park JA, et al. (2021) Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. Journal of hematology & oncology, 14(1), 142.

Zavareh RB, et al. (2021) HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins. Cell chemical biology, 28(2), 158.

Lim J, et al. (2019) Kazinol U inhibits melanogenesis through the inhibition of tyrosinase-related proteins via AMP kinase activation. British journal of pharmacology, 176(5), 737.

Wallstabe L, et al. (2018) CAR T cells targeting ??v??3 integrin are effective against advanced cancer in preclinical models. Advances in cell and gene therapy, 1(2).